The Novo Nordisk Foundation and its investment company Novo Holdings welcome the opportunity to respond to the European Commission's Call for Evidence on the European Biotech Act. Advancing biotech capabilities is essential for positioning the EU at the forefront of technology, fostering growth in sectors crucial for sustainable socioeconomic development and security.
NNF
Novo Nordisk Foundation
NGO · Denmark · EU Transparency Register 097928945982-83
2
positions filed
in the 326 files tracked
2
legislative files
of 326 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 784 non-governmental organisations on this site, they rank #385 by legislative files engaged — a count of participation, not a measure of influence.
4
declared lobbying FTE
self-declared
—
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2022
in the register since
Declares membership of
- NNF is member of the following organisations:
- Bio-based Industry Consortium
- Philanthropy Europe Association
- European Food Forum
- and Contributing partner of EDCTP3 call(s)
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Non-governmental organisations
- Head office
- Hellerup, Denmark
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Novo in PolicySpeak: request access →
Work at Novo Nordisk Foundation? so we know who speaks for it.
Their record over time
Novo Nordisk Foundation filed 2 positions between 11 Jun 2025 and 9 Jun 2026, across 2 of the 326 legislative files tracked here, attaching a full position paper 2 times.
2025 · 1 filed2026 · 1 filed
What they argued
Biotechnology is a strategic enabler of Europes competitiveness, sustainability, and resilience. Despite strong scientific capabilities, Europe continues to lag in translating research into industrial scale and market deployment, held back by regulatory complexity, limited biomanufacturing capacity, weak market demand, and investment gaps.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 2 files in common
- Cefic · 2 files in common
- Danish Industry · 2 files in common
- German Association of Biotechnology Industries (DIB) within the German Chemical Industry Association - VCI · 2 files in common
- BASF SE · 2 files in common
Showing 5 of 80.
Is this your organization?
Everything on this page comes from Novo Nordisk Foundation’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.